Anti-β-Alzheimer Therapies Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Anti-β-Alzheimer Therapies Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Alzheimer’s disease (AD) is a type of neurological disorder that mainly affects thinking, memory, language, and behavior. This disease mainly occurs in people who are above 65 age and older and it has mild symptoms but results in severe brain damage in which individuals lose the ability to speak properly and respond to the environment. According to the Alzheimer Association, 2017, more than 5.5 million Americans are suffering from Alzheimer’s dementia. An estimated 5.3 million are age 65 and older and approximately 200,000 individuals are under age 65 and have the onset of Alzheimer’s. Alzheimer’s cognitive and behavioral symptoms can be treated by using non-drug treatment and symptomatic-based medications. However, specific treatment for Alzheimer’s disease is not available in the market, which creates an opportunity for the development of Anti- β- Alzheimer therapies.
A breakthrough therapy is expected to offer immense growth for the Anti-β-Alzheimer therapies market
In July 2015, Biogen Pharmaceuticals announced results from a prespecified interim analysis of PRIME, which was the Phase 1b placebo-controlled study of aducanumab in patients with prodromal or mild Alzheimer’s disease (AD). Phase I clinical trials were conducted on 166, patients, which showed significant progress by lowering of Amyloid beta levels in the brain and slowdown in cognitive function as compared to the control group who received a placebo. Phase III efficacy trial showed significant cognitive results in FDA based specific memory tests. On the other hand, in 2016, Eli Lilly and Company announced the development of Alzheimer’s drug solanezumab, which was in phase III clinical trial due to its slow progression of Alzheimer’s disease and high cost.
In 2012, Pfizer Inc. and Johnson & Johnson announced to discontinue the development of Alzheimer’s drug which was in intravenous (IV) form – bapineuzumab as drug failed to help the patient with the memory-robbing condition in a second high profile clinical trial. Such failures, limit the growth of a market.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1204
Reasons to Purchase this Report
• Current and future of global Anti-β-Alzheimer Therapies market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1204
Rising prevalence and incidence of Alzheimer disease is projected to favor the growth of Anti-β-Alzheimer therapies market
A growing aging population along with its associated complications, such as dementia is the major driving factor for the growth of the Anti-β-Alzheimer therapies market. For instance, according to Centers for Disease Control and Prevention (CDC), 2013, five million Americans were suffering from AD and the number is expected to rise up to 14 million by 2050. Moreover, according to the World Health Organization (WHO), 2017, approximately 47 million people have dementia and nearly 10 million new cases are reported annually.
According to the Australian Bureau of Statistics (ABS) in 2013, dementia was the second leading cause of death in Australia. According to the Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach around 400,000 by 2020, and around 900,000 by 2050. The National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to priorities and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment and care for dementia patients. Rising prevalence and incidence of Alzheimer disease and its complication worldwide and growing demand for therapy is projected to favor the growth of Anti-β-Alzheimer therapies market in the near future.
Biogen Pharmaceuticals is a key player dominating the global Anti-β-Alzheimer therapies market.
Global Anti-β-Alzheimer Therapies Market Taxonomy:
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Ask for PDF sample copy of the Anti-β-Alzheimer Therapies market report @ https://www.coherentmarketinsights.com/insight/request-pdf/1204
Major Point Answered in Anti-β-Alzheimer Therapies Market Research Study are: –
• What will the market growth rate, Overview, and Analysis by Type of Anti-β-Alzheimer Therapies market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Anti-β-Alzheimer Therapies market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Anti-β-Alzheimer Therapies market?
• Who are the Opportunities, Risk, and Driving Force of the Anti-β-Alzheimer Therapies market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in the Anti-β-Alzheimer Therapies market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Anti-β-Alzheimer Therapies market opportunities and threats faced by the vendors in the market?
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027